Product Description
AKO001 is comprised of the psychedelic compound N,N-dimethyltryptamine (DMT) and a specific plant bioactive which, when combined together, are believed to work in a complementary and mitigating manner when provided to individuals immediately following their ischemic stroke. (Sourced from: https://www.akomebiotech.com/ako001-for-stroke/)
Mechanisms of Action: TAAR1 Agonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Core One Labs
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/02/2022 |
News Article |
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT |
|
04/02/2022 |
News Article |
Core One Labs' Akome Receives Positive Results from Bioassay Studies |
|
08/07/2021 |
News Article |
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development |